What is the treatment for neuroleptic malignant syndrome (NMS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Neuroleptic Malignant Syndrome

Immediately discontinue all antipsychotic medications and initiate aggressive supportive care—this is the single most critical intervention that reduces mortality from 76% to less than 10-15%. 1

Immediate Management Steps

Discontinue Offending Agents

  • Stop all antipsychotic medications immediately upon suspicion of NMS—this is the first and most essential step, even before diagnostic confirmation is complete. 1
  • Avoid physical restraints as they worsen isometric muscle contractions, exacerbating hyperthermia and lactic acidosis, thereby increasing mortality. 1

Aggressive Supportive Care

  • Treat agitation with benzodiazepines rather than additional antipsychotics or physical restraints. 1
  • Implement external cooling measures for hyperthermia, including cooling blankets and ice packs. 1, 2
  • Administer IV fluids aggressively to address dehydration, autonomic instability, normalize vital signs, and prevent rhabdomyolysis-induced renal failure. 1, 2

Pharmacologic Interventions for Severe Cases

Dopaminergic Agents

  • Bromocriptine (oral dopamine agonist) should be used in severe cases to address central dopamine deficiency caused by antipsychotic blockade. 1, 3, 4
  • This is particularly important when rigidity and hyperthermia are prominent features. 5

Muscle Relaxants

  • Dantrolene sodium (IV) should be administered to reduce muscle rigidity and hyperthermia in severe cases by acting directly on skeletal muscle. 1, 4, 5
  • The combination of dantrolene and bromocriptine has shown dramatic favorable responses in severe NMS. 4, 5

Critical Care Interventions

For Extreme Hyperthermia (>41.1°C)

  • Emergency sedation, neuromuscular paralysis, and intubation may be required. 1
  • Approximately 25% of NMS patients require ICU admission. 1

Hemodialysis

  • Initiate hemodialysis if renal failure develops from rhabdomyolysis. 2

Second-Line Treatment

Electroconvulsive Therapy (ECT)

  • ECT is indicated as second-line treatment for severe and persistent NMS, particularly when the patient has a concurrent psychiatric condition that would benefit from ECT or when pharmacologic interventions fail. 1, 3, 4

Essential Monitoring

Laboratory Surveillance

  • Obtain complete blood count, electrolytes, renal function, liver function, creatine kinase, arterial blood gases, and coagulation studies. 1
  • Monitor for complications including rhabdomyolysis with elevated creatine kinase, metabolic acidosis, elevated liver enzymes, renal failure, seizures, and disseminated intravascular coagulation. 1

Common Pitfalls to Avoid

  • Do not use anticholinergics liberally—while they may enhance bromocriptine effectiveness, they can worsen hyperthermia and autonomic instability. 4
  • Do not delay treatment waiting for diagnostic confirmation—early recognition and prompt management are crucial for improving outcomes. 1, 6
  • Do not rechallenge with antipsychotics for at least 2 weeks following complete resolution of NMS symptoms. 6

References

Guideline

Treatment of Neuroleptic Malignant Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Neuroleptic Malignant Syndrome (NMS) Clinical Presentation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical management of neuroleptic malignant syndrome.

The Psychiatric quarterly, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.